Stimulant Use
18
6
7
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
5.6%
1 terminated out of 18 trials
88.9%
+2.4% vs benchmark
0%
0 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (18)
THRIVE: Culturally AdapTed Harm Reduction Intervention
Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City
Enhancing Prospective Thinking in Early Recovery
PrEP Affect Regulation Treatment Innovation
Supporting Treatment Adherence for Resilience and Thriving (START)
Financial Incentives to Promote Stimulant Abstinence in a Community-Based Syringe Exchange Program
Project neuroARTEMIS
Neuromodulation and Cognitive Training for Substance Use Disorders
Accelerated rTMS for Substance Use Disorder and Depression
rTMS for Stimulant Use Disorders
The Longitudinal Study of Stimulant Use Disorder
Drugs Brain and Behavior (DDP)
Acute Effects of Stimulant Medication in College Students With ADHD
Change in Cognitive Function in Stimulant Users
rTMS for Craving in Methamphetamine Use Disorder
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
Relapse Prevention in Stimulant Use Disorder
Contingency Management for Stimulant Use Disorders